Back to search results

Hypofractionated External Beam Radiotherapy for Endometrial and Cervical Cancers

This study is looking at a type of radiation therapy called hypofractionated external beam radiotherapy for women who have had surgery for endometrial or cervical cancer. This treatment delivers the total radiation dose in fewer, larger sessions compared to standard radiation. Researchers want to see if this approach, using CT or MRI guidance, can be just as effective with similar side effects, but with fewer treatment visits for you. The study will evaluate how well you tolerate the treatment and any side effects you might experience. We are planning to enroll 60 participants, and the current recruitment status is unclear.

Study design
This is an interventional study, meaning all 60 participants will receive the study treatment. It is not specified if this study is randomized or blinded.
What's involved
You would receive 5 radiation therapy sessions, delivered every other day (excluding weekends/holidays). You will be in the study for about 5 years, with follow-up visits after radiation therapy.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for acute radiation toxicity from the start of treatment to 12 weeks after completing radiotherapy. You will also have follow-up visits with a radiation oncologist within the first 3 months after completing radiation therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06538337

Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers

Recruiting
NAAges 18+InterventionalTreatment
Jonsson Comprehensive Cancer Center
~60 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:External beam Radiotherapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Evaluate acute radiation toxicity
Measured over treatment to 12 weeks after completion of radiotherapy

Conditions

Endometrial Cancer
Cervical Cancer

Explore related trials

Cervical CarcinomaEndometrial Carcinoma

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Puja S. Venkat, MD · PRINCIPAL_INVESTIGATOR · University of California at Los Angeles

Who to contact

Christy Palodichuk
[email protected]
310-794-2971
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically confirmed endometrial or cervical cancer
Surgical resection of the primary tumor
International Federation of Gynecology and Obstetrics (FIGO) Stage IA-IVB endometrial cancer OR FIGO Stage IA-IIA cervical cancer that meets indications for receiving adjuvant pelvic radiotherapy alone as standard of care
Age ≥ 18 years old
Karnofsky performance status (KPS) ≥ 60 or Eastern Cooperative Oncology Group (ECOG) 0-2

Exclusion

Must not meet indications for receiving concurrent chemotherapy as standard of care
Active treatment of a separate malignancy
History of prior irradiation to the area to be treated

What this trial measures

  • Evaluate acute radiation toxicitytreatment to 12 weeks after completion of radiotherapy

    Evaluate acute radiation toxicity according to Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0). Acute toxicity is defined as treatment-related adverse events occurring within 12 weeks of completion of radiotherapy.